English
Structure via PubChem · Public domain (PubChem)
cartazolate
Sign in to saveCartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R. Squibb and Sons in the 1970s.
Chemical data
- Formula
- C15H22N4O2
- Molecular weight
- 290.36 g/mol
- IUPAC name
- ethyl 4-(butylamino)-1-ethylpyrazolo[3,4-b]pyridine-5-carboxylate
- SMILES
- CCCCNC1=C2C=NN(C2=NC=C1C(=O)OCC)CC
- InChIKey
- IQNQAOGGWGCROX-UHFFFAOYSA-N
- XLogP
- 3.1
- Polar surface area
- 69 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 290.174
Show 4 more facts
- chemical formula
- C₁₅H₂₂N₄O₂
- canonical SMILES
- CCCCNC1=C2C=NN(C2=NC=C1C(=O)OCC)CC
- different from
- tracazolate
- Commons category
- Cartazolate
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R. Squibb and Sons in the 1970s.
== See also == Etazolate ICI-190,622 Tracazolate
Excerpted from Wikipedia’s “cartazolate” article, available under the CC BY-SA 4.0 licence.